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Summary
Background Heavy menstrual bleeding affects 25% of women in the UK, many of whom require surgery to treat it. 
Hysterectomy is effective but has more complications than endometrial ablation, which is less invasive but ultimately 
leads to hysterectomy in 20% of women. We compared laparoscopic supracervical hysterectomy with endometrial 
ablation in women seeking surgical treatment for heavy menstrual bleeding.
Methods In this parallel-group, multicentre, open-label, randomised controlled trial in 31 hospitals in the UK, 
women younger than 50 years who were referred to a gynaecologist for surgical treatment of heavy menstrual 
bleeding and who were eligible for endometrial ablation were randomly allocated (1:1) to either laparoscopic 
supracervical hysterectomy or second generation endometrial ablation. Women were randomly assigned by either 
an interactive voice response telephone system or an internet-based application with a minimisation algorithm 
based on centre and age group (<40 years vs ≥40 years). Laparoscopic supracervical hysterectomy involves laparoscopic 
(keyhole) surgery to remove the upper part of the uterus (the body) containing the endometrium. Endometrial 
ablation aims to treat heavy menstrual bleeding by destroying the endometrium, which is responsible for heavy 
periods. The co-primary clinical outcomes were patient satisfaction and condition-specific quality of life, measured 
with the menorrhagia multi-attribute quality of life scale (MMAS), assessed at 15 months after randomisation. Our 
analysis was based on the intention-to-treat principle. The trial was registered with the ISRCTN registry, number 
ISRCTN49013893.
Findings Between May 21, 2014, and March 28, 2017, we enrolled and randomly assigned 660 women (330 in each 
group). 616 (93%) of 660 women were operated on within the study period, 588 (95%) of whom received the allocated 
procedure and 28 (5%) of whom had an alternative surgery. At 15 months after randomisation, more women allocated 
to laparoscopic supracervical hysterectomy were satisfied with their operation compared with those in the endometrial 
ablation group (270 [97%] of 278 women vs 244 [87%] of 280 women; adjusted percentage difference 9·8, 95% CI 
5·1–14·5; adjusted odds ratio [OR] 2·53, 95% CI 1·83–3·48; p<0·0001). Women randomly assigned to laparoscopic 
supracervical hysterectomy were also more likely to have the best possible MMAS score of 100 than women assigned 
to endometrial ablation (180 [69%] of 262 women vs 146 [54%] of 268 women; adjusted percentage difference 13·3, 
95% CI 3·8–22·8; adjusted OR 1·87, 95% CI 1·31–2·67; p=0·00058). 14 (5%) of 309 women in the laparoscopic 
supracervical hysterectomy group and 11 (4%) of 307 women in the endometrial ablation group had at least one 
serious adverse event (adjusted OR 1·30, 95% CI 0·56–3·02; p=0·54).
Interpretation Laparoscopic supracervical hysterectomy is superior to endometrial ablation in terms of clinical 
effectiveness and has a similar proportion of complications, but takes longer to perform and is associated with a 
longer recovery.
Funding UK National Institute for Health Research Health Technology Assessment Programme.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 
license.
Introduction
Heavy menstrual bleeding, which affects a quarter of 
women in the UK,1 accounts for around a fifth of all 
hospital gynaecology referrals and has a profound effect 
on quality of life.2 In the USA, the condition leads to a 
three times increase in hospitalisation compared with 
age-matched control patients who do not have heavy 
menstrual bleeding3 and imposes a major economic 
burden on society because of the costs of treatment and 
loss of productivity.4 The initial approach to treatment of 
heavy menstrual bleeding is medical, but treatment 
failure is high. Up to 77% of women on oral drugs and 
42% of those using the levonorgestrel intrauterine 
system (Mirena; Bayer, Leverkusen, Germany) need to 
undergo surgical treatment within 5 years.5 More than a 
third (38%) of women referred to an English National 
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Health Service (NHS) hospital between April, 2009, and 
March, 2012, with heavy menstrual bleeding received 
surgery,2 and in the USA the corresponding figure 
was 63%.3
The two most common surgical treatments for heavy 
menstrual bleeding are endometrial ablation, where the 
endometrium is thermally destroyed but the uterus is 
preserved, and hysterectomy, where the uterus is 
removed.6 Endometrial ablation does not require 
surgical incisions and newer (second generation) 
techniques are simple to learn, quick to perform, and 
associated with rapid recovery and early return to work.7 
Various energy sources can be used for endometrial 
ablation, but the most common are radiofrequency 
energy (Novasure; Hologic, Marlborough, MA, USA) or 
heated, fluid filled balloons.8
Hysterectomy can be done in several different ways, but 
total hysterectomy (ie, removal of the uterus and cervix) 
by open surgery remains the most widely used technique 
in the UK.2 Total laparoscopic hysterectomy avoids large 
abdominal incisions, requires a shorter hospital stay, and 
facilitates quicker recovery. However, this procedure takes 
longer, requires advanced laparoscopic skills, and has 
more complications compared with conventional open 
surgery.9 Laparoscopic supracervical hysterec tomy only 
requires removal of the uterine body, which is the main 
source of heavy menstrual bleeding. This strategy offers a 
less complex alternative that avoids difficult surgical 
dissection around the cervix and bladder, reducing the 
risk of urinary tract injury and bleeding.10 The availability 
of newer surgical equipment has simplified laparoscopic 
supracervical hysterectomy and this fact, combined with 
improvements in laparoscopic training, has made the 
procedure accessible to most gynaecologists.
Although endometrial ablation is an effective, 
minimally invasive, and uterine sparing treatment for 
heavy menstrual bleeding, almost 20% of women who 
have this treatment will ultimately require a hysterectomy 
for relief of their symptoms.11 An individual participant 
data meta-analysis of randomised trials showed that 
total hysterectomy was superior to endometrial ablation 
in terms of clinical and cost effectiveness,12,13 but was 
associated with a longer hospital stay, slower recovery, 
and a higher risk of surgical complications.14 Further-
more, total hysterectomy could predispose a woman to 
development of bladder symptoms, such as urgency and 
stress incontinence.11,15,16 Two small randomised trials 
suggested that laparoscopic supracervical hysterectomy 
could achieve outcomes similar to those after total 
hysterectomy but with quicker recovery and fewer 
complications.17,18 A Cochrane review on this topic 
recommended a head-to-head comparison of second 
generation endometrial ablation with more recent types 
of hysterectomy, including laparoscopic supracervical 
hysterectomy.14 We aimed to compare the clinical 
effective ness of laparoscopic supracervical hysterectomy 
with endometrial ablation in women opting for surgical 
treatment for heavy menstrual bleeding.
Research in context
Evidence before this study
Heavy menstrual bleeding is a common problem that affects 
around 1·5 million women in England and Wales and has a 
substantial negative effect on their quality of life. The National 
Institute for Health and Care Excellence recommends 
endometrial ablation or hysterectomy as surgical options for 
women with heavy menstrual bleeding that is resistant to 
medical treatment. We searched PubMed and the Cochrane 
Library in 2013 and updated the search on Dec 27, 2018, 
with the search terms “heavy menstrual bleeding”, 
“hysterectomy”, “endometrial ablation”, “randomised trial”, 
and “systematic review”, with no language restrictions. 
An individual participant data meta-analysis published in 2014 
showed that fewer women are dissatisfied with conventional 
hysterectomy than with endometrial ablation, but the former 
option is more invasive, involves a longer hospital stay, and 
prolonged recovery time. A health economic model based on 
these data showed that hysterectomy was more cost-effective. 
A Health Technology Assessment monograph from the same 
research group indicated that 25% of all women undergo 
subsequent gynaecological surgery following endometrial 
ablation, with just under a fifth requiring hysterectomy. These 
findings are consistent with those of a relevant Cochrane 
review, which concluded that the optimal surgical treatment for 
heavy menstrual bleeding unresponsive to medical treatment 
might be hysterectomy, but the effectiveness of this treatment 
needs to be balanced against its invasiveness and increased 
short-term and long-term morbidity.
Added value of this study
This trial showed that a less invasive alternative to conventional 
hysterectomy—laparoscopic supracervical hysterectomy—was 
more effective than endometrial ablation without increasing 
surgical risk. Laparoscopic supracervical hysterectomy was 
clinically superior to endometrial ablation in terms of 
satisfaction (270 [97%] of 278 patients vs 244 [87%] of 
280 patients; adjusted percentage difference 9·8, 95% CI 
5·1–14·5; adjusted odds ratio [OR] 2·53, 95% CI 1·83–3·48; 
p<0·0001) and quality of life as assessed by the menorrhagia 
multi-attribute quality-of-life scale (adjusted OR 1·87, 95% CI 
1·31–2·67; p=0·00058). Serious adverse event numbers were 
low and similar for both procedures.
Implications of all the available evidence
This study shows that a less invasive form of hysterectomy can 
result in high satisfaction associated with removal of the 
uterus and low morbidity, which is similar to less invasive 
surgery, such as endometrial ablation.
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Methods
Study design and participants
The HEALTH study was a multicentre, parallel-group, 
open-label, randomised controlled trial in 31 hospitals in 
the UK. The trial protocol has been published previously.19 
Participants were women younger than 50 years with no 
desire for (further) children who were referred to a 
gynaecologist for surgical treatment of heavy menstrual 
bleeding. Inclusion criteria were eligibility for endometrial 
ablation (fibroids <3 cm, uterine cavity size <11 cm, and 
absence of endometrial pathology on biopsy) and normal 
cervical cytology. Women were excluded if they had 
undergone a previous endometrial ablation, if laparo-
scopic surgery was contraindicated, or if they were unable 
to give informed consent or complete trial paperwork.
Patients gave written informed consent for inclusion in 
the study. The study was centrally approved by the North of 
Scotland Research Ethics Service (reference no 13/NS/0155) 
for all 31 centres and was done according to the principles 
of good clinical practice provided by research governance 
guidelines.
Randomisation and masking
Women were randomly assigned (1:1) to laparoscopic 
supracervical hysterectomy or second generation endo-
metrial ablation by either an Interactive Voice Response 
telephone system or an internet-based application with a 
minimisation algorithm based on centre and age group 
(<40 years vs ≥40 years). Participants were enrolled by 
dedicated research nurses who used a remote web-based 
randomisation application at the Centre for Healthcare 
Randomised Trials (CHaRT; University of Aberdeen, 
Aberdeen, UK) for group allocation. The research nurses 
were not involved in the collection of primary outcome 
data. Surgeons and participants could not be masked to 
the allocated procedure because of the nature of the 
interventions.
Procedures
After randomisation, participants were placed on the 
NHS surgical waiting list for the appropriate treatment. 
As per Scottish and UK Government guidelines, it 
was anticipated that treatment would occur within 
12–18 weeks of random assignment.20,21 Principal 
investigators from all 31 participating hospitals were 
members of the British Society of Gynaecological 
Endoscopy. Each responsible surgeon was certified 
competent for both procedures as per usual NHS and 
good clinical practice requirements, but the technique 
used was not modified for the purposes of the trial. All 
other aspects of care were left to the discretion of the 
responsible surgeon.
Laparoscopic supracervical hysterectomy involves 
laparoscopic (keyhole) surgery to remove the upper part 
of the uterus (the body) containing the endometrium. As 
the cervix is not removed, complex dissection, which 
potentially increases the risk of injury to surrounding 
structures like the bladder, ureters, and blood vessels, 
can be avoided.9,22 Cervical cancer screening is still 
required and, although most women will cease to have 
periods after the procedure, light menstrual bleeding or 
cyclical spotting can occur in 5–20% of women.23,24
The body of the uterus is detached from the cervix 
usually with a monopolar or bipolar wire loop after 
sealing the uterine vessels. The body is removed through 
a 10–12-mm port sited either within the umbilicus or 
suprapubically with a power morcellator that converts 
the specimen into strips of tissue. This process can be 
done inside a bag to prevent spread of fragmented tissue 
within the peritoneal cavity. Alternatively, the complete 
unmorcellated specimen can be removed through an 
internal incision at the top of the vagina (culdotomy).
Endometrial ablation aims to treat heavy menstrual 
bleeding by destroying the endometrium, which is 
responsible for heavy periods. First generation endome-
trial ablation techniques involve an operating hystero-
scope and a loop, ball, or laser energy and, although 
effective, are difficult to learn and highly operator 
dependent. The more commonly used second generation 
endometrial ablation techniques involve devices that are 
inserted into the uterine cavity that, when activated, will 
destroy the endometrium and superficial myometrium, 
containing endometrial glands, up to 6 mm. Other than 
the actual insertion of the device into the uterine cavity, 
these techniques tend not to be operator dependent.
Second generation procedures used in the UK and 
recommended by The National Institute for Health and 
Care Excellence (NICE)6 include thermal balloon endo-
metrial ablation and radiofrequency energy (Novasure). 
Thermal balloon endometrial ablation is achieved by 
means of a silicone balloon that is introduced through 
the cervix into the uterine cavity. The balloon fills and 
expands to conform to the inside of the uterine cavity, 
compressing the endometrium. Hot fluid circulating 
within the balloon ensures endometrial destruction and 
the temperature and duration of treatment is carefully 
controlled electronically by means of a computer attached 
to the device. Novasure uses radiofrequency energy 
delivered through an intrauterine mesh electrode that 
expands after insertion through the cervix to fit the shape 
of the uterine cavity. The energy required is calculated by 
the device and treatment times are under 90 s. These 
treatments substantially reduce menstrual bleeding and 
result in complete cessation of bleeding in up to 50% of 
women.8 Second generation endometrial ablation can be 
done as a day case procedure, either under general or 
local anaesthetic. Although suitable for use in the 
outpatient setting, most endometrial ablations (94%) are 
done in operating theatres in the UK.25
The local research team at each centre collected intra-
operative and post-operative data at the time of the 
randomly assigned procedure and completed a short 
case report form for any related hospital readmissions 
during the follow-up period. Participant-reported 
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outcomes were assessed by self-completed question-
naires at baseline (before surgery), 6 weeks, and 6 months 
after surgery, and 15 months after randomisation. A self-
completed 14-day diary was also collected. We sent non-
responders up to two reminders by either post, email, 
telephone, or text message depending on the woman’s 
preferred method of com munication. Pathology results 
for all endometrial biopsies and uterine specimens were 
also obtained.
We had a 15-month follow-up period after randomisation 
to accommodate the 12–18 week waiting time for treatment. 
Our intention was that participants would complete their 
primary outcome questionnaire (triggered 15 months after 
randomisation) approximately 12 months after surgery to 
facilitate comparisons with outcomes from other similar 
trials in the literature.
Outcomes
The co-primary clinical outcomes assessed at 15 months 
after randomisation were patient satisfaction, measured 
on a six point Likert scale (from totally satisfied to totally 
dissatisfied),26 and the menorrhagia multi-attribute quality 
of life scale (MMAS), which provides a condition-specific 
quality of life outcome27 ranging from 0 (worst possible 
health state) to 100 (best possible health state) based on 
six items, measured at 15 months after randomisation.
Secondary outcome measures were MMAS at 6 months 
after surgery; patient-reported satisfaction at 6 months 
after surgery; self-reported pain score at days 1–14 and 
6 weeks after surgery; acceptability of treatment at 
6 weeks after surgery; men strual outcomes at 6 months 
after surgery and 15 months after randomisation; 
symptom diary on days 1 to 14 after surgery; generic 
health-related quality of life (assessed with the short 
form 12 [SF-12; 0 represents the worst possible quality of 
life and 100 the best possible quality of life] comprising a 
physical component score and mental component score, 
and EuroQol Group 5 dimension health status ques-
tionnaire [EQ-5D-3L; utility score: –0·59 represents the 
worst possible quality of life and 1·00 the best possible 
quality of life; visual analogue scale: 0 represents the 
worst imaginable health state and 100 the best possible 
health state] at 6 weeks, 6 months after sur gery and 
15 months after randomisation); duration of operation; 
peri-operative complications and recovery details, 
including analgesia requirements, time for dis charge, 
and need for additional gynaecological surgery by 
15 months after randomisation; and wider societal 
costs associated with changes in productivity based on 
information and the time taken to return to normal 
activities combined with questions on work productivity 
delivered during the follow-up period.
The co-ordinating study team was notified of adverse 
events either directly by local researchers or through 
entries in follow-up questionnaires completed by partici-
pants. The local research team verified suspected adverse 
events where possible. We did not record unrelated 
Figure: Trial profile
*Reasons were unwillingness to have surgery (one patient), private treatment (one patient), and no reason 
given (one patient). †Reasons were unwillingness to have surgery (two patients), requested a different operation 
(two patients), family illness (one patient), moved abroad (one patient), and did not want to complete 
questionnaires (two patients). ‡Excluding withdrawn patients but including the 19 patients in each group who 
did not receive treatment.
333 assigned to endometrial ablation
330 correctly randomised
    328 completed baseline questionnaire
3 randomised in error
2552 patients screened
 
664 randomly assigned
 
1888 excluded
     1201 ineligible
       589 declined inclusion
         98 clinical preference
 
307 received treatment
297 received allocated treatment
1 received laparoscopic supracervical 
hysterectomy
9 received other treatment
5 total hysterectomy
4 hysteroscopic polypectomy
 
267 of 307 completed 14-day post-surgery diary
23 did not receive treatment
    19 no operation
    4 withdrawn†
251 of 306 completed 6-week post-surgery diary
1 withdrawn†
244 of 305 completed 6-month post-surgery 
diary
1 withdrawn†
284 of 322‡ completed 12-month post-surgery 
(15-month post-randomisation) diary
330 analysed for primary outcome
2 withdrawn†
331 assigned to laparoscopic supracervical 
hysterectomy
330 correctly randomised
     327 completed baseline questionnaire
1 randomised in error
309 received treatment
     291 received allocated treatment
     12 received endometrial ablation
       6 received other treatment
              5 total hysterectomy
              1 hysteroscopic polypectomy
267 of 309 completed 14-day post-surgery diary
21 did not receive treatment
     19 no operation
     2 withdrawn*
255 of 309 completed 6-week post-surgery diary
254 of 308 completed 6-month post-surgery 
diary
1 withdrawn*
280 of 327‡ completed 12-month post-surgery 
(15-month post-randomisation) diary
330 analysed for primary outcome
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adverse events. Serious adverse events were defined by 
use of standard classifications.28
Statistical analysis
We powered the HEALTH study to detect a difference 
in satisfaction of 8% (assuming 95% overall satisfaction 
after total hysterectomy and 87% overall satisfaction after 
endometrial ablation).12 We required outcome data on 
292 participants for 90% power, assuming a two-sided 
significance level of 5%, inflated to 324 participants to 
allow for 10% attrition in the primary outcome. To retain 
a significance level of 5% for the primary outcome 
analysis, we specified a hierarchy for testing the primary 
outcomes—MMAS was only examined if the result for 
patient satisfaction was statistically significant (p<0·05). 
This trial also had more than 90% power to detect a 
ten-point difference in MMAS, assuming an SD of 
33 units.
We used appropriate descriptive statistics to summarise 
data at all timepoints, with mean (SD) or median (IQR) 
for continuous data, and frequencies and percentages for 
categorical data. Our analysis was based on the intention-
to-treat principle—partici pants were analysed by 
randomised group and not by the treatment received.
We used ordinal logistic regression to analyse both 
co-primary outcomes. This decision was made after 
discussion with the independent data monitoring 
committee, which met on Oct 17, 2017, after they raised 
concerns about the appropriateness of the methods in 
our original analysis plan given the distribution of 
outcome data in an interim report (without considering 
any emerging treatment effect). For full details of the 
rationale for this change and the implications for power 
in the revised analysis plan see the appendix (pp 1–24). 
Analysis of patient satisfaction used the following four 
categories: totally satisfied, generally satisfied, fairly 
satisfied, and fairly, generally, or totally dissatisfied. 
MMAS was coded as an ordinal variable with the 
following four categories: ≤50, 51–75, 76–99, and 100 
(maximum score), because of the extreme skewness of 
this outcome at follow-up. We checked the proportional 
odds assumption was appropriate by examining the odds 
ratios (ORs) from binary logistic regression for the three 
binary splits of the data (for satisfaction: totally satisfied 
vs other, totally or generally satisfied vs other, and satisfied 
vs dissatisfied; for MMAS: 0–99 vs 100, 0–75 vs 76–100, 
and 0–50 vs 51–100) and by Brant test with a significance 
threshold of p<0·001. We analysed secondary outcomes 
with generalised linear models with appropriate link 
functions for the distribution of the outcome. We used 
repeated measures regression for the pain score recorded 
in the patient diary in the first two weeks after surgery. 
Details of categories used in ordinal logistic regression 
models for skewed continuous variables are shown in the 
appendix (pp 41–42).
We did not make any adjustments for multiple testing. 
Analyses of all primary and secondary outcomes were 
adjusted for the minimisation variables age group and 
centre (treated as a random effect) and for a relevant 
baseline score if available. We did several sensitivity and 
subgroup analyses for the primary outcomes. These 
included an unadjusted ordinal logistic regression 
analysis, binary logistic regression analyses for each split 
of the data, analyses using multiple imputation, a per 
protocol analysis, an analysis restricted to operations 
done by a consultant, and a linear regression analysis 
for MMAS (appendix pp 25–26, 30–32). 95% CIs are 
provided for all measures of effect.
For the co-primary outcomes, we also did exploratory 
subgroup analyses for the following prespecified vari-
ables: uterine cavity length (≤8 cm vs >8 cm), menstrual 
pain (dysmenorrhea) at baseline (severe or crippling pain 
vs other categories), patient age (<40 years vs ≥40 years), 
and presence or absence of fibroids. These tests were 
done by including a treatment by subgroup interaction 
term in the corresponding ordinal logistic regression 
model.
We used Stata 15.1 for all analyses. The trial was 
registered with the ISRCTN registry, number 
ISRCTN49013893.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data inter pretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
Between May 21, 2014, and March 28, 2017, we enrolled 
and randomly assigned 660 women (330 in each group; 
Laparoscopic supracervical 
endometrial ablation (n=330)
Endometrial ablation 
(n=330)
Age (years) 42 (5) 42 (5)
Body-mass index (kg/m²) 29·1 (5·6) [309] 29·0 (5·3) [304]
Pre-operative haemoglobin (g/L) 131·0 (13·1) [306] 130·1 (12·6) [282]
Number of caesarean sections 0 (0–1) [326] 0 (0–1) [327]
Very heavy periods with clots and flooding 261/327 (80%) 259/327 (79%)
Periods with severe dysmenorrhoea 170/326 (52%) 160/326 (49%)
Pain at intercourse 193/299 (65%) 186/306 (61%)
Bladder symptoms (urinary urgency, 
stress incontinence, or both)
188/323 (58%) 178/325 (55%)
Baseline outcome scores
Menorrhagia multi-attribute quality of 
life scale total score
28·6 (14·7–43·7) [323] 29 (15·7–47·7) [321]
EQ-5D-3L 0·76 (0·66–1·00) [319] 0·79 (0·69–1·00) [322]
EQ-5D-3L visual analogue scale 70 (50–85) [317] 70 (52–85) [321]
SF-12 physical component summary 45·0 (9·0) [318] 44·9 (9·7) [321]
SF-12 mental component summary 37·2 (11·0) [318] 38·7 (11·6) [321]
Data are mean (SD), n/N (%), or median (IQR). N in square brackets indicates the valid N for continuous data where there 
were missing data at baseline. EQ-5D-3L=EuroQol questionnaire, five dimensions, three levels. SF-12=short form 12.
Table 1: Baseline characteristics
See Online for appendix
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figure). The study groups were similar at baseline in 
terms of age, severity, and duration of symptoms (table 1). 
616 (93%) of 660 women were operated on within the 
study period, 588 (95%) of whom received the allocated 
procedure and 28 (5%) of whom had an alternative 
surgery.
At 15 months after randomisation, more women allo-
cated to laparoscopic supracervical hysterectomy were 
satisfied with their operation compared with those in the 
endometrial ablation group (270 [97%] of 278 women 
vs 244 [87%] of 280 women; adjusted percentage 
difference 9·8, 95% CI 5·1–14·5; adjusted OR 2·53, 
1·83–3·48; p<0·0001; table 2). Women randomly assigned 
to laparoscopic supracervical hyster ectomy were also 
more likely to have the best possible MMAS score of 100 
than were women assigned to endometrial ablation 
(180 [69%] of 262 women vs 146 [54%] of 268 women; 
adjusted percentage differ ence 13·3, 95% CI 3·8–22·8; 
adjusted OR 1·87, 1·31–2·67; p=0·0058; table 2).
Fewer women in the laparoscopic supracervical 
hysterectomy group continued to have periods (adjusted 
OR 0·32, 95% CI 0·21–0·48; p<0·0001), cyclical period-
like pelvic pain (0·31, 0·22–0·44; p<0·0001), or 
pain during intercourse (0·61, 0·41–0·91; p=0·015) 
compared with women in the endometrial ablation 
group. We observed no clinically or statistically significant 
difference in the proportion of women reporting 
bladder symptoms (urinary urgency, stress, or mixed 
incontinence; 0·97, 0·73–1·29; p=0·83; table 2).
Women randomly assigned to endometrial ablation 
reported higher EQ-5D-5L utility and SF-12 physical 
component scores 6 weeks after surgery (appendix 
pp 35–36). By 15 months after randomisation, women in 
the laparoscopic supracervical hysterectomy group had 
better scores for the EQ-5D-3L visual analogue scale 
(adjusted OR 1·50, 95% CI 1·12 to 1·99; p=0·0057) and 
the SF-12 mental component score (adjusted mean 
difference 2·47, 1·07 to 3·87; p=0·0012; table 2). We 
observed no clinically or statistically significant differences 
between the groups regarding the EQ-5D-3L utility score 
(adjusted OR 1·21, 0·89 to 1·64; p=0·23) or SF-12 physical 
component score (adjusted mean difference 1·08, 
–0·65 to 2·81; p=0·21) at 15 months (table 2). All 6-months 
post procedure data are reported in the appendix 
(pp 35–42) and were similar to the primary outcome 
measures at 15 months after randomisation.
Laparoscopic supracervical hysterectomy was associ-
ated with increased operating times and length of 
Laparoscopic supracervical 
hysterectomy (n=330)
Endometrial ablation (n=330) Adjusted effect size (95% CI) p value
Satisfaction ·· ·· 2·53* (1·83 to 3·48) <0·0001
Totally satisfied 211/278 (76%) 158/280 (56%) ·· ··
Generally satisfied 40/278 (14%) 57/280 (20%) ·· ··
Fairly satisfied 19/278 (7%) 29/280 (10%) ·· ··
Fairly, generally, or totally dissatisfied 8/278 (3%) 36/280 (13%) ·· ··
Overall satisfaction (fairly, generally, or totally 
satisfied)
270/278 (97%) 244/280 (87%) 9·80† (5·08 to 14·51) 0·00089
Total menorrhagia multi-attribute quality-of-
life score
·· ·· 1·87* (1·31 to 2·67) 0·00058
100 180/262 (69%) 146/268 (54%) ·· ··
76–99 50/262 (19%) 59/268 (22%) ·· ··
51–75 17/262 (6%) 34/268 (13%) ·· ··
0–50 15/262 (6%) 29/268 (11%) ·· ··
Secondary outcomes
Continuing periods 52/277 (19%) 117/277 (42%) 0·32* (0·21 to 0·48) <0·0001
Cyclical (period-like) pelvic pain 71/224 (32%) 118/196 (60%) 0·31* (0·22 to 0·44) <0·0001
Pain at intercourse 62/213 (29%) 80/204 (39%) 0·61* (0·41 to 0·91) 0·015
Bladder symptoms 116/232 (50%) 113/223 (51%) 0·97* (0·73 to 1·29) 0·83
Recommend treatment to friend 263/271 (97%) 246/280 (88%) 4·52* (2·14 to 9·53) <0·0001
Quality of life
EQ-5D-3L utility score 1·00 (0·73–1·00) [281] 0·85 (0·72–1·00) [281] 1·21* (0·89 to 1·64) 0·23
EQ-5D-3L visual analogue scale 85 (70–90) [279] 80 (65–90) [282] 1·50* (1·12 to 1·99) 0·0057
SF-12 physical component score 53·5 (8·9) [219] 52·4 (9·0) [216] 1·08‡ (–0·65 to 2·81) 0·21
SF-12 mental component score 48·5 (11·2) [219] 46·6 (11·1) [216] 2·47‡ (1·07 to 3·87) 0·0012
Data are n/N (%), median (IQR), or mean (SD), unless otherwise indicated. N in square brackets indicates the denominator or valid N where there was missing data. All 
estimates adjusted for age group, centre, and baseline score (where applicable). EQ-5D-3L=EuroQol questionnaire, five dimensions, three levels. SF-12=short form 12. *Odds 
ratio from ordinal logistic regression or binary logistic regression. †Adjusted difference in percentages for those satisfied (all categories) versus other. ‡Difference in means 
from linear regression. 
Table 2: Primary and selected secondary outcomes at 15 months after randomisation
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hospital stay (table 3). 99 (32%) of 306 women allocated 
to laparoscopic supracervical hysterectomy had a post-
operative hospital stay of more than 24 h compared with 
16 (5%) of 303 women in the endometrial ablation group. 
More women randomly assigned to laparoscopic supra-
cervical hysterectomy were noted to have subserosal or 
intramural fibroids during surgery (table 3). 14 (5%) of 
309 women in the laparoscopic supracervical hyster-
ectomy group and 11 (4%) of 307 women in the endo-
metrial ablation group had at least one serious adverse 
event (adjusted OR 1·30, 95% CI 0·56–3·02; p=0·54; 
table 4). One woman in the laparoscopic supracervical 
hysterectomy group had two adverse events (infection 
and catheterisation). Other complications were rare, but 
there were more instances of immediate short-term 
voiding difficulties in the laparoscopic supracervical 
hysterectomy group (table 4).
18 (6%) of 307 women randomly assigned to endome-
trial ablation and two (1%) of 309 women randomly 
assigned to laparoscopic supracervical hysterectomy 
received further surgery during the follow-up period 
(table 4). The most common reason for further surgery 
was insufficient reduction in heavy menstrual bleeding 
following the index endometrial ablation procedure 
(12 patients). One woman who was randomly assigned to 
laparoscopic supracervical hysterectomy required a 
second procedure to remove the cervical stump because 
of ongoing pain and bleeding. A further seven women 
required unplanned further surgery because the index 
endometrial ablation procedure could not be completed 
on the first attempt. Hysterectomy was the second 
procedure on five occasions.
Women randomly assigned to laparoscopic supra-
cervical hysterectomy had higher pain scores (0=no pain, 
10=worst imaginable pain) in the first 2 weeks after 
surgery than those randomly assigned to endometrial 
ablation (marginal mean 3·39, SE 0·12 vs 2·48, 0·12); 
adjusted mean difference 0·92, 95% CI 0·59–1·24; 
p<0·0001; appendix pp 33–34) and more pain at 6 weeks 
(adjusted OR 1·43, 95% CI 1·05–1·96; p=0·025; appendix 
p 34), although the proportion of women with any 
pain symptoms was 157 (61%) of 256 assigned to laparo-
scopic supracervical hysterectomy versus 94 (39%) of 
243 assigned to endometrial ablation (adjusted per-
centage difference 23, 95% CI 15–31) at 2 weeks and 
89 (37%) of 241 assigned to laparoscopic supracervical 
hysterectomy versus 67 (29%) of 234 assigned to endo-
metrial ablation (8·7, 1·6–15·8) at 6 weeks. At 2 weeks 
after the procedure, median pain scores were 1 (IQR 0–3) 
in the laparoscopic supracervical hysterectomy group 
versus 0 (0–2) in the endometrial ablation group; at 
6 weeks median pain score was 0 (0–1) in both groups.
Women in the endometrial ablation group were able to 
return earlier to paid work (median 42 days, IQR 37–42 in 
the laparoscopic supracervical hysterectomy group vs 
10 days, 7–14 in the endometrial ablation group; adjusted 
hazard ratio 0·23, 95% CI 0·18–0·30; p<0·0001), unpaid 
work (21 days, 17–25 in the lapa roscopic supracervical 
hysterectomy group vs 7 days, 5–7 in the endometrial 
ablation group; 0·64, 0·57–0·73; p<0·0001), and sporting 
or social activities (42 days, 34–42 in the laparoscopic 
supracervical hysterectomy group vs 14 days, 14–18 in the 
endometrial ablation group; 0·48, 0·42–0·56; p<0·0001; 
appendix p 34).
At 15 months after randomisation, women in the 
laparoscopic supracervical hysterectomy group were 
more likely to recommend their treatment to a friend 
(263 [97%] of 271 women vs 246 [90%] of 280 women; 
adjusted OR 4·52, 95% CI 2·14–9·53; p<0·0001; 
appendix p 37).
The results of our sensitivity analyses did not alter our 
interpretation of the primary outcomes (appendix 
pp 30–32). Women with fibroids who were randomly 
assigned to laparoscopic supracervical hysterectomy 
reported better levels of satisfaction than those randomly 
assigned to endometrial ablation (OR 7·27, 95% CI 
2·32–41·8; p=0·0019; appendix p 32). We observed no 
Laparoscopic supracervical 
hysterectomy (n=309)
Endometrial ablation 
(n=307)
Procedure received*
Laparoscopic supracervical hysterectomy 291 (94%) 1 (<1%)
Endometrial ablation 12 (4%) 297 (97%)
Total hysterectomy 5 (2%) 5 (2%)
Hysteroscopy or polypectomy 1 (<1%) 4 (1%)
Uterine cavity length (cm) 8·38 (1·63) [259] 7·24 (1·97) [292]
Fibroids†
Type 0 or 1 fibroid ≤3 cm 11 (4%) 11 (4%)
Type 2 fibroids ≤3 cm 9 (3%) 6 (2%)
Intramural or subserosal fibroids ≤3 cm 50 (17%) 10 (3%)
Not known 15 5
Duration of operation‡ (min) 114 (38) [306] 44 (23) [295]
Post-operative analgesia
Paracetamol or ibuprofen 269 (87%) 226 (74%)
Oral opiate 136 (44%) 72 (23%)
Opiate injection 94 (30%) 46 (15%)
Time to discharge from operation (h) 21·5 (17·0–26·1) [306] 3·2 (2·1–5·1) [303]
Hospital stay >24 h (with reason if known)
No 207 (68%) 287 (95%)
Yes
Pain 30 (10%) 3 (1%)
Nausea or vomiting 2 (1%) 1 (<1%)
Social or geographical 13 (4%) 2 (1%)
Voiding problems 14 (5%) 1 (<1%)
Other reason 13 (4%) 4 (1%)
Reason unknown 27 (9%) 5 (2%)
Not recorded 3 4
Data are n (%), mean (SD), or median (IQR). N in square brackets indicates the valid N for continuous data where there 
were missing data at baseline. *38 women (19 in each group) did not undergo surgical treatment for heavy menstrual 
bleeding during the study period. †Fibroids detected at baseline scan and at hysteroscopy or laparoscopic supracervical 
hysterectomy procedure. ‡Time from entry to anaesthetic room to exit from operating room (min).
Table 3: Surgical details for index procedure
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clinically or statistically significant differences in 
satisfaction or MMAS scores for any other of the 
subgroups on the basis of cavity length (≤8 cm vs >8 cm), 
age (<40 years vs ≥40 years), or symptoms of 
dysmenorrhoea (appendix p 32). We found no differences 
between baseline factors when comparing women who 
did and did not provide primary outcome data at 
15 months (data not shown).
Discussion
This large randomised trial compared the two most 
commonly recommended surgical treatments for heavy 
menstrual bleeding (endometrial ablation and hyster-
ectomy) in terms of patient-centred outcomes. At 
15 months after randomisation, lapa roscopic supra-
cervical hysterectomy resulted in signifi cantly higher 
satisfaction and better quality of life compared with 
endometrial ablation. Despite being a longer procedure 
with a slower recovery time, laparoscopic supracervical 
hysterectomy led to a greater improvement in menstrual 
blood loss, cyclical period-like pain, and dyspareunia, 
without incurring a higher risk of postoperative 
complications or precipitating bladder-related symptoms. 
The pragmatic multicentre nature of this trial is likely to 
enhance the generalisability of our findings.
Loss to follow-up in our trial was higher than 
anticipated. Although this is a limitation, we were able 
to achieve a response rate of more than 80% for the 
co-primary outcomes, and the overall results were 
unaffected in our sensitivity analyses. We were also 
unable to enforce a standard interval between randomi-
sation and surgery. The NHS waiting list target of 
3 months for routine operations prompted us to collect 
primary outcome data at 15 months after randomisation. 
Our expectation was that this strategy would allow a 
minimum of 12 months of follow-up but a tenth of 
women (balanced across the two study groups) faced 
delays in receiving treatment because of waiting list 
pressures or inability to attend hospital for surgery due to 
illness. In 14 (2%) of 616 participants, this delay resulted 
in an overlap between the 6-month post-surgery and 
15-month post-randomisation questionnaires.
More subserosal and intramural fibroids were reported 
in the laparoscopic supracervical hysterectomy group. 
This finding was not entirely unexpected, as this strategy 
allows visual detection of small subserosal fibroids that 
can be missed at a baseline ultrasound scan. Although 
randomisation might have resulted in similar numbers 
of fibroids (both detected and undetected) in both groups, 
outcomes were better in those randomly assigned to 
laparoscopic supracervical hysterectomy.
Our results show a clear clinical benefit associated with 
both surgical techniques but measures of satisfaction, 
quality-of-life scores, and outcomes such as amenorrhoea, 
residual menstrual bleeding, and pelvic pain were more 
positive for laparoscopic supracervical hyster ectomy 
compared with endometrial ablation. Specifically, only 
3% of women in the laparoscopic supracervical 
hysterectomy group reported dissatisfaction compared 
with 13% of women in the endometrial ablation group. 
69% of women assigned to laparoscopic supra cervical 
hysterectomy achieved a maximum condition-specific 
quality-of-life MMAS score of 100, compared with 55% of 
those assigned to endometrial ablation. Although both 
procedures were associated with a reduction in symptoms 
of dyspareunia, improvement was more marked in 
women in the laparoscopic supracervical hysterectomy 
group, possibly because the uterus was removed. Thus, 
laparoscopic supracervical hysterectomy appears to be a 
more effective surgical treatment for heavy menstrual 
bleeding than endometrial ablation.
At recruitment, the physical and mental components of 
the SF-12 generic quality-of-life questionnaire in all 
participants with heavy menstrual bleeding were lower 
than normative values for healthy women of an equivalent 
age,29 with mental health scores being particularly low. By 
15 months after randomisation, the physical component 
in both trial groups and the mental component in the 
laparoscopic supracervical hysterectomy group had 
returned to normative values.29 Although those allocated 
to endometrial ablation reported higher generic quality of 
life values at 6 weeks, possibly representing quicker 
recovery, by 15 months the visual analogue scale of 
EQ-5D and the mental component of SF-12 favoured 
those allocated to laparoscopic supracervical hysterectomy.
Laparoscopic 
supracervical 
hysterectomy 
(n=309)
Endometrial 
ablation 
(n=307)
Any serious adverse event* 14 (5%) 11 (4%)
Infection 5 (2%) 5 (2%)
Pain 3 (1%) 4 (1%)
Catheterisation for longer than 72 h 3 (1%) 1 (<1%)
Conversion to hysterectomy 1† (<1%) 1 (<1%)
Readmitted for investigation of 
shortness of breath
1 (<1%) 0
Prolonged admission for 
observation only
1 (<1%) 0
Bladder injury 1 (<1%) 0
Other complications
Voiding dysfunction 14 (5%) 2 (1%)
Consultation for pain 1 (<1%) 1 (<1%)
Haematoma 1 (<1%) 1 (<1%)
Blood loss >500 mL 1 (<1%) 1 (<1%)
Uterine perforation, inactive or blunt 1 (<1%) 3 (1%)
Pyrexia requiring antibiotics 3 (1%) 2 (1%)
Blood transfusion 0 1 (<1%)
Further operation by 15 months after 
randomisation
2 (1%) 18 (6%)
Data are (n%). *Numbers refer to participants, not events. †One woman 
randomised to laparoscopic supracervical hysterectomy received endometrial 
ablation but underwent conversion to total hysterectomy.
Table 4: Serious adverse events and complications
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A previous individual participant data meta-analysis 
found total hysterectomy to be more effective than endo-
metrial ablation, with dissatisfaction rates of 5% versus 
15%,12,13 although total abdominal hysterectomy was noted 
to be more invasive than endometrial ablation, with 
higher morbidity and prolonged recovery times.12 The 
HEALTH trial has shown that outcomes after laparoscopic 
supracervical hysterectomy are similar to those achieved 
after total hysterectomy but with lower morbidity (<5%), 
which is similar to endometrial ablation. These relative 
benefits of laparoscopic supracervical hysterectomy 
should be offset against the longer total theatre time 
(almost 2 h compared with 45 min for endometrial 
ablation), early post-operative pain, greater duration of 
hospital stay (one in three women staying more than 24 h 
after the procedure compared with one in five for 
endometrial ablation), and prolonged recovery times 
(mean return to social or sporting activities of 42 days 
compared with 14 days).
The results of our predetermined subgroup analyses 
showed that the presence of fibroids was associated with 
poorer outcomes after endometrial ablation compared 
with laparoscopic supracervical hysterectomy. However, 
because of the small patient numbers and the differential 
detection of fibroids between the two groups, this result 
should be interpreted with caution. Age (<40 years vs 
≥40 years), symptoms of dysmenorrhoea, or cavity length 
(≤8 cm vs >8 cm) did not have a significant effect upon 
clinical outcomes.
Both endometrial ablation and laparoscopic supra-
cervical hysterectomy improved menstrual symptoms. 
81% of patients having amenorrhoea after laparoscopic 
supracervical hysterectomy corresponds with longer-
term published data,24 but amenorrhoea in women after 
endometrial ablation was higher in our trial than the 
40–50% reported in the literature.7 Our results correspond 
with those reported in a systematic review and individual 
participant data meta-analysis of trials comparing 
total hysterectomy with endometrial ablation,12 despite 
the fact that laparoscopic supracervical hysterectomy 
preserves the cervix and does not guarantee amenorrhoea. 
Two smaller randomised trials compared endometrial 
ablation with laparoscopic supracervical hysterectomy17,18 
and support our findings, although the time to discharge 
after laparoscopic supra cervical hysterectomy was longer 
in our trial. This difference could reflect the culture 
within a public health-care system and traditional post-
surgical expectations of patients, relatives, and clinical 
staff. The introduction of specific enhanced recovery 
programmes,30 which were not a statutory part of 
postoperative care for laparoscopic supracervical hyster-
ectomy in our trial, might reduce the length of hospital 
stay in the future. Despite a median pain score of 1 
2 weeks after laparoscopic supracervical hysterectomy, 
return to normal activities was almost 6 weeks. This 
difference might reflect historical advice for allowed and 
expected convalescence after hysterectomy given by 
family doctors and nurses in the UK, and should be 
addressed through education and information packages 
to account for different approaches to undertaking this 
common operation.
This trial supports the previously reported reduced risk 
of complications with laparoscopic supracervical hyster-
ectomy, which was comparable to endometrial ablation 
and much lower than for total hysterectomy. We found 
no evidence of bladder symptoms (urinary urgency, 
stress, or mixed incontinence) being negatively affected 
after laparoscopic supracervical hysterectomy.
The main disadvantage of laparoscopic supracervical 
hysterectomy compared with total hysterectomy is 
ongoing cyclical bleeding from the retained cervical 
stump. A Cochrane review of total versus subtotal 
hysterectomy suggested a cyclical bleeding rate of 
5–10% after laparoscopic supracervical hysterectomy,23 
although a higher rate of 23% has been reported by 
Lieng and colleagues.24 Despite routine electrosurgical 
cauterisation of the cervical canal after removal of the 
body of the uterus, in our trial 19% of women in the 
laparoscopic supracervical hysterectomy group continued 
to have light cyclical bleeding or spotting.
The higher number of reoperations in the endometrial 
ablation group is supported by the literature, which 
suggests that almost 20% of women undergoing endo-
metrial ablation will have a hysterectomy within 5 years.11 
The number of subsequent surgeries after laparoscopic 
supracervical hysterectomy is not well known, although 
figures around 7% have been reported by 3 years.24 
The proportions of reoperations required will have an 
effect on cost-effectiveness and could influence patient 
preference for one treatment over the other.
Our trial reflects contemporary practice in the UK, where 
NICE defines heavy menstrual bleeding as excessive 
menstrual bleeding that affects a woman’s quality of life 
and recommends the levonorgestrel releasing intrauterine 
system or an alternative medical treatment as the first step 
in women with no identified pathology or fibroids less 
than 3 cm in diameter.8 When this strategy is unsuccessful, 
symptoms are severe, or pharmacological treatment is 
declined, women are referred to specialist care where 
the options include surgery (endometrial ablation or 
hysterectomy). As our eligible population comprised 
women with heavy menstrual bleeding referred by their 
general practitioners to gynaecology clinics, we expect our 
results to be gen eralisable to women who have been 
previously offered medical treatment. In this population, 
laparoscopic supracervical hysterectomy was found to be 
more effective than endometrial ablation for treating heavy 
menstrual bleeding without the risk of complications 
associated with total hysterectomy.9,22 Thus, for gynaecol-
ogists with intermediate laparoscopic skills, laparoscopic 
supracervical hysterectomy provides an effective, mini-
mally invasive surgical option that has the potential to 
reduce the number of open hysterectomies and their 
attendant complications and slow recovery times.12
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As in this trial, most second-generation endometrial 
ablations are still done under general anaesthetic in an 
operating theatre, but the procedure can be done under 
local anaesthetic in an outpatient setting.31 Newer, 
portable, small-diameter ablative devices with quick 
treatment times should encourage movement of endo-
metrial ablation out of the traditional operating theatre. 
Our trial results could help inform greater choice for 
women with heavy menstrual bleeding seeking sur-
gical treatment. Laparoscopic supracervical hysterectomy 
could be offered to women who want a general anaes-
thetic for their procedure and who are accepting of a 
longer recovery time. By contrast, endometrial ablation 
could be offered as a convenient outpatient procedure in 
women who are content to have local anaesthetic and 
who prioritise a less invasive procedure with quicker 
recovery over potentially reduced effectiveness.
Concerns have been raised about the potential risk of 
disseminating cells from undiagnosed uterine malig-
nancy associated with the use of morcellators during 
laparoscopic hysterectomy in women with fibroids.32,33 
Risk factors highlighted by an updated estimate of 
leiomyosarcoma incidence at hysterectomy include age 
older than 50 years and the presence of larger fibroids,34 
both of which were exclusion criteria for the HEALTH 
trial. We were reassured by the absence of any histological 
abnormalities in this trial, including women with known 
fibroids of less than 3 cm in diameter. However, a high 
level of vigilance is required for hysterectomy where 
fibroids are present, and morcellation should be avoided if 
there are concerns of malignant changes within a fibroid. 
In the absence of accurate biomarkers, this decision 
would need to be based on morphological features or 
evidence of rapid growth. Morcellation within containment 
bags or removal of the uterus via a culdotomy are options 
for preventing tissue fragment dissemination. The risk of 
overlooking latent malignancy within a presumed fibroid 
is also relevant in all women undergoing endometrial 
ablation or any other conservative treatment for heavy 
menstrual bleeding where the uterus is preserved.
Laparoscopic supracervical hysterectomy was intro-
duced because of its simplicity and potential to reduce 
surgical morbidity. However, further advances in instru-
mentation, improved training, and greater familiarity 
with laparoscopic surgery, combined with a greater 
appreciation of interventions to enhance surgical recovery 
might reduce these relative benefits of laparoscopic 
supracervical hysterectomy over total laparoscopic hyster-
ectomy. Future trials comparing the two laparoscopic 
approaches to hysterectomy could help elucidate their 
relative advantages and disadvantages. Given the greater 
effectiveness of laparoscopic supracervical hysterectomy, 
albeit with longer operating times, hospital stay, and 
recovery time, a comprehensive heath economic evalu-
ation of the two procedures over a medium-term to long-
term time horizon is indicated. Such a study is currently 
being done by our group. Additionally, we intend to 
undertake longer-term follow-up of clinical and quality-of-
life outcomes and further interventions for both study 
groups.
In conclusion, laparoscopic supracervical hysterectomy 
is more effective than endometrial ablation, without any 
additional risk of complications, but this treatment takes 
longer and is associated with increased time to full 
recovery. With an increasing number of options available 
for women with heavy menstrual bleeding it is important 
to explore how these techniques and the attributes 
associated with them—for example, care delivery 
systems, wish for amenorrhoea, and willingness to have 
treatment in a formal operating theatre or hospital 
setting—can influence patient choice. Methods of 
reducing recovery times and associated costs after 
surgery, including enhanced recovery interventions and 
packages of care, need further evaluation. Add itionally, 
although endometrial ablation has been shown to be safe 
and acceptable under local anaesthetic, the reasons why 
most procedures are still undertaken in traditional 
theatre settings needs further investigation.
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